Use of sphingomyelin and non-digestible carbohydrates for improving intestinal microbiota
AssigneeN. V. Nutricia
InventorsWillem Ferdinand Nieuwenhuizen, Kaouther Ben Amor, Jan Knol, Eline Marleen Van Der Beek, Christopher Beermann, Guenther Boehm
Life of this patent
Estimating the term…
Abstract
A composition comprising sphingophospholipid or its degradation product and at least one non-digestible carbohydrate for providing and/or maintaining an optimal intestinal microbiota is provided. The composition is especially suitable for infant nutrition.
Claims19
-12. (canceled)
A method of normalising the intestinal microbiota in a human subject towards the microbiota found in healthy lean subjects and/or to breast-fed infants, comprising administering to the subject a nutritional composition comprising:
- (a) sphingophospholipid and/or at least one sphingophosholipid degradation product selected from the group consisting of ceramide, lysosphingophospholipid, sphingoid phosphate, and free sphingoid base, and
- (b) at least fructo-oligosaccharides and galacto-oligosaccharides, wherein the intestinal microbiota is normalised with respect to an increased prebiotic index and/or an increased ratio Bifidobacteria/total bacteria.
A method for the prevention of obesity and/or adiposity, comprising administering to a human subject in need thereof a composition comprising:
- (a) sphingophospholipid, preferably sphingomyelin, and/or at least one sphingophosholipid degradation product selected from the group consisting of ceramide, lysosphingophospholipid, sphingoid phosphate, and free sphingoid base, and
- (b) at least fructo-oligosaccharides and galacto-oligosaccharides.
A method for the treatment and/or prevention of gastrointestinal infection, diarrhoea and/or gastrointestinal inflammation, allergy, asthma, atopic dermatitis, eczema, systemic infections and respiratory infections comprising administering to a human subject in need thereof a composition comprising:
- (a) sphingophospholipid, preferably sphingomyelin, and/or at least one sphingophosholipid degradation product selected from the group consisting of ceramide, lysosphingophospholipid, sphingoid phosphate, and free sphingoid base, and
- (b) at least fructo-oligosaccharides and galacto-oligosaccharides.
Dependencies are inferred from the claim text.